A research lab for one
Hey YC! We're Alfredo and Ranad, the founders of Omanta.
TL;DR: Omanta creates a personalized research lab around a single patient. We integrate a patient’s complete medical record, personal genomics, and use AI to take on the most complex cancer cases. Our researchers tackled GitLab co-founder Sid Sijbrandij’s case, helping bring him into complete remission.
https://www.youtube.com/watch?v=EkZaq_fENqI
Why this matters
If you're a cancer patient, you'd think the hardest cases have entire teams dedicated to solving them. The reality: most doctors have about 20 minutes per patient, while the science never stops moving. New discoveries emerge every day, yet reaching standard clinical care can take over a decade (~17 years on average). Physicians make high-stakes decisions with limited time, and even the most difficult cases rarely have anyone whose full-time job is to interrogate every layer of that one patient's disease and push the newest science toward their treatment.
That's the gap we built Omanta to close.
What we do
We meet patients wherever they are in their journey. We integrate their complete medical record and personal genomics with AI and clinical evidence to understand the molecular drivers of their disease. Then we map every existing therapy against their biology, and if the right therapy doesn't exist, we build it, from cancer vaccines and immunotherapies to highly targeted radioligand therapies.
We've worked on some of the most complex cancer cases in the world. Most notably, Alfredo was the genomics lead for the personalized therapeutic campaign behind GitLab founder Sid Sijbrandij's complete remission, partnering with leading institutions to pursue personalized mRNA/DNA vaccines, CAR-T programs, drug repurposing, expanded-access therapies, and continuous molecular monitoring. We've seen what becomes possible when the full force of modern science is organized around a single person, and Omanta brings that depth of investigation to every case.
Why us
We met eight years ago working on early CRISPR cancer research and have been building toward this ever since.
- Alfredo Gonzalez, PhD (CEO) — translational genomics. Led the year-long investigation of 25TB of sequencing and molecular data for Sid Sijbrandij, key missing information in existing genomic reports, and uncovered actionable findings that reshaped his therapeutic strategy, including personalized mRNA/DNA vaccines, CAR-T, expanded access, drug repurposing, and continuous monitoring. PhD at UCLA, where he built one of the world's largest centralized multi-omic datasets for rare tumors. Previously at the Broad Institute (Cancer Dependency Map, validating targets from large-scale CRISPR screens) and Harvard's Wagers Lab.
- Ranad Humeidi, PhD (CSO) — chemical biologist. Earned her PhD in Chemical Biology from Harvard in three years, where she identified a druggable mechanism in ulcerative colitis that became the basis of a multimillion-dollar GSK collaboration. Built and directed a multimillion-dollar scientific program centered on a single rare-cancer patient, then went on to direct scientific strategy for 12+ medically complex patients after standard options were exhausted. At the Broad, she co-created and co-led a fellowship turning scientific discoveries into companies.
Our ask
- Intros. If you or someone you love is facing a difficult cancer diagnosis, we want to hear from you.
- We're also looking to connect with physicians who want a dedicated research team behind their most complex cases.
- Reach us here on Bookface or at alfredo@omanta.com & ranad@omanta.com.
omanta.com
A research lab, for one.
